Compare Cipla with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs GLENMARK PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA GLENMARK PHARMA CIPLA/
GLENMARK PHARMA
 
P/E (TTM) x 29.4 14.6 201.5% View Chart
P/BV x 4.2 2.4 173.4% View Chart
Dividend Yield % 0.5 0.4 117.2%  

Financials

 CIPLA   GLENMARK PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-20
GLENMARK PHARMA
Mar-19
CIPLA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs586712 82.3%   
Low Rs357484 73.8%   
Sales per share (Unadj.) Rs207.0349.6 59.2%  
Earnings per share (Unadj.) Rs18.632.8 56.7%  
Cash flow per share (Unadj.) Rs33.244.3 74.8%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.80.3 253.7%  
Book value per share (Unadj.) Rs195.5198.6 98.4%  
Shares outstanding (eoy) m806.35282.17 285.8%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.31.7 133.1%   
Avg P/E ratio x25.318.2 139.0%  
P/CF ratio (eoy) x14.213.5 105.4%  
Price / Book Value ratio x2.43.0 80.1%  
Dividend payout %21.56.1 352.6%   
Avg Mkt Cap Rs m379,912168,625 225.3%   
No. of employees `00025.812.0 214.7%   
Total wages/salary Rs m30,27020,561 147.2%   
Avg. sales/employee Rs Th6,459.68,196.0 78.8%   
Avg. wages/employee Rs Th1,171.21,708.1 68.6%   
Avg. net profit/employee Rs Th580.2768.5 75.5%   
INCOME DATA
Net Sales Rs m166,94998,655 169.2%  
Other income Rs m3,4422,081 165.4%   
Total revenues Rs m170,391100,736 169.1%   
Gross profit Rs m32,06015,858 202.2%  
Depreciation Rs m11,7473,259 360.4%   
Interest Rs m1,9743,346 59.0%   
Profit before tax Rs m21,78211,335 192.2%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m6,3123,756 168.0%   
Profit after tax Rs m14,9959,250 162.1%  
Gross profit margin %19.216.1 119.5%  
Effective tax rate %29.033.1 87.4%   
Net profit margin %9.09.4 95.8%  
BALANCE SHEET DATA
Current assets Rs m117,03866,968 174.8%   
Current liabilities Rs m43,93140,211 109.3%   
Net working cap to sales %43.827.1 161.5%  
Current ratio x2.71.7 160.0%  
Inventory Days Days9683 114.9%  
Debtors Days Days8581 104.8%  
Net fixed assets Rs m107,42433,322 322.4%   
Share capital Rs m1,613282 571.4%   
"Free" reserves Rs m156,01855,770 279.8%   
Net worth Rs m157,63056,052 281.2%   
Long term debt Rs m23,69335,738 66.3%   
Total assets Rs m236,626132,888 178.1%  
Interest coverage x12.04.4 274.3%   
Debt to equity ratio x0.20.6 23.6%  
Sales to assets ratio x0.70.7 95.0%   
Return on assets %7.29.5 75.7%  
Return on equity %9.516.5 57.6%  
Return on capital %12.817.8 72.1%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,03662,998 88.9%   
Fx outflow Rs m6,76422,859 29.6%   
Net fx Rs m49,27240,140 122.8%   
CASH FLOW
From Operations Rs m30,68513,242 231.7%  
From Investments Rs m1,040-6,990 -14.9%  
From Financial Activity Rs m-29,488-7,387 399.2%  
Net Cashflow Rs m2,340-2,971 -78.8%  

Share Holding

Indian Promoters % 16.0 48.3 33.1%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 6.9 176.8%  
FIIs % 23.7 34.4 68.9%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.5 249.5%  
Shareholders   161,166 56,727 284.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   J.B.CHEMICALS  SUVEN LIFE SCIENCES  WYETH  ELDER PHARMA  VENUS REMEDIES  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Open Higher; JSW Steel & Tata Steel Top Gainers(09:30 am)

Asian share markets edged higher today as investors shrugged off concerns that stocks may have rallied too far too fast in the past year.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Mar 3, 2021 11:06 AM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS